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Milan. Italy 
O&jectives. This 6-month follow-up analysis sought to assess 
whether the early reduction of mortality obtained with a bweek 
treatment course of lisioopril or glyceryl trhdtrate, or both, in 
unselected patients with acute myocardii infarction outlasts 
therapy and is still present after 6 months. The primary outcome 
of the Q-month folhnv-up was the combined eud point of mortality 
and severe left ventricular dysfunctiou. 
Bodrgfuund. The assumption was that tbe early heneflt on 
remodeling processes may he maintained over a longer period of 
time, even in the absence of treatment. 
M&oak A total of 19,394 patients with acute myocatvlial 
infarctlou welp randomiaed within 24 b of onset of symptoms to a 
6-week treatment course of oral lisinopril or open control and, 
according to a 2 X 2 factorial design, to glycetyl trinitrate or open 
absence of specific indications, and the patients were followed up 
for 6 months. 
ResuU.s. At 6 months, amoug patients randomired to lisinopril, 
10.1% died or developed severe ventrictdar dysfunctiou versus 
19.3% of those txuuiomimd to no lisiuopril (2p = 0.93). No 
difference was found between patients with and without glyceryl 
trinitrate therapy (18.4% vs. lL9%,2p = 039). 
Condusion. Although the systematic administration of glyc- 
etyl ttiuitrate statted early aud couthtued for 6 weeks after acute 
myocnrdiiiufarctiidoesuotyieldev&uceofheuetlt+eorly 
treatment witb lisiuopril appears te huprove prognosis This e&t 
seemstoearryoverttwfirst6wathshamraodomizatioa,w~ 
after treatment withdrawal. 
(JAm Coil Chid 19%;27:337-44) 
The report of the 6-month results of the Gruppo Italian0 per 
lo Studio della Soprawivenza nell’lnfartb Miocardico 
(GIN)-3 trial (I) does not simply represent an account of the 
medium-term consequences of a randomized treatment started 
in the very ear!, phase of acute myocardial infarction, as has 
been the case for previous GISSI trials (2.3). According to the 
study protocol (4) the 6-month follow-up was planned to 
answer a specific question not formally addressed by other 
trials: Does a very early exposure to angiotensin-converting 
enzyme inhibitors or glyceryl trinitrate express itself better or 
exclusively during treatment (6 weeks after acute myocardial 
infarction) or as a medium-term benefit measurahle at 6 
months after treatment discontinuation? To formally test this 
hypothesis, which relied’ largely on the attenuation of the 
remodeling processes after acute myocardial infarction (5.6). 
*A fompieic Ikn of investigators and participating oznten appears in 
reference 1. Organizational information for GIW-3 is provided in the Appendi 
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randomized treatments (lisinopril and transdermal glyceryl 
trinitrate) were stopped after 6 weeks. According to the study 
protocol, outcome events were also different, mortality being 
the primary end point for the 6-week treatment hypothesis ano 
the combination of mortality plus severe left ventricular dys- 
function (1.7) representing the primary end point for the 
6-month evaluation. Therefore, after the report on the 6week 
results on mortality, which have recently been confirmed by the 
results of International Study of Infarct Survival (!SIS)-4 (8) 
and Chinese Cardiac Study (KS)-I (9) the present study is 
focused on the combined end point of mortality and severe left 
ventricular dysfunction at 6 months. 
Methods 
Patients. The GISSI-3 protocol has been fully described 
elsewhere ($4). In brief, patients admitted to the participant 
coronary care units were eligible for central randomizatioru 
1) if they presented chest pain accompanied by elevation or 
depression of the ST segment of at least 1 mm in one or more 
peripheral leads or of at least 2 mm in one or more precordial 
leads; 2) if they bad been admitted ,to the coronary care units 
within 24 h of symptom onset; and 3) if they had no clear 
contraindications to the study treatments. No age restriction 
was imposed. Patients were ineligible for raudumiratiou (4) if 
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they were at Sigh risk of developing further serious hemody- 
namic deterioration after treatment with vasodilators (systolic 
blood pressure at entry ~100 mm Hg) and if they had a history 
of dinicahy relevant renal dysfunction (serum creatinine 
>177 pmoI/Iiter or proteinuria >500 mg per 24 h, or both). 
Patients were randomly assigned to oral lisinopril(5 mg at 
randomization, 5 mg after 24 h, 10 mg after 48 h, then 10 mg 
once daily for 6 weeks) or open control. Subjects with systolic 
blood pressure between 100 and 120 mm Hg at randomization 
or in the first 3 days could be given a lower dose of Iisinopril 
(2.5 mg). Patients were also randomly assigned to glyceryl 
trinitrate or open control. Glyceryl trinitrate was administered 
during the first 24 h by intravenous infusion. After 24 h, the 
intravenous infusion was replaced with a transdermal patch 
providing 10 mg of glyceryI trinitrate da@. The patch was 
applied early every morning and removed at bedtime to 
provide a 10-h nitrate-free interval so as to minimize pharma- 
cologic tolerance. 
Mortality and severe left ventricular dysfunction were as- 
sessed after 6 weeks of treatment to check for possible effects 
of the study treatments. In the absence of specific indications 
(i.e., hypertension, angina, congestive heart failure;, treatment 
was then stopped at the 6-week visit, and the patients were 
followed up to 6 months from randomization to determine 
whether the benefit shown with an early 6-week treatment was 
maintained after drug withdrawal. This was assessed by means 
of a combined end point that consisted of death, clinical heart 
failure or left ventricular dysfunction (&IO). 
To minimize the potential bias arising from the open 
design, a consetvative criterion was adopted to define clinical 
heart failure after discharge, namely, the presence of New 
York Heart Association functional class III or IV. Extensive 
left ventricular damage was identified by the presence of a left 
ventricular ejection fraction of 35% or less on two-dimensional 
echocardiography; if the ejection fraction was not available. 
extensive left ventricular damage was deemed present if ~45% 
of myocardial segments appeared injured at echocardiography 
(10). The criteria for central quality control of the echo 
recordings have been described elsewhere (1). 
The participating coronary care units were also asked to 
report all clinically relevant events (postinfarction angina. 
reinfarction, sustained ventricular tachycardia, revasculariza- 
tion procedures) occurring following trial admission. Informa- 
tion on survival of patients not traced by the coronary care 
units was obtained by telephone or through census ofhces. 
StatisthA methads. The data on the combined end point 
were analyzed according to the intention to treat principle 
using the same comparisons adopted for the (i-week period 
(i.e., lisinopril vs. no lisinopril, transdermal glyceryl trinitrate 
vs. no transdermal gIycery1 trinitrate, lisinopril plus transder- 
mal glyceryi trinitrate vs. neither, in the overall population, and 
in the prespecified populations of elderly patients and women). 
The cm-square statistic was used for significance testing on 
categoric variables. The results are presented in terms of 
Mantel-HaenszeCPeto odds ratios with their 95% confidence 
intervals. All p values are two-tailed. 
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66 (0.37%) 
lost to 6month 
follow-up 
17,w.l 
patients with 
6.month data 
/\ 
15,679 2,261 
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Figure 1. Flowchart for GISSI-3 trial, 
Results 
A comprehensive picture of the patient population is 
provrded in the flowchart of Figure 1. The previous report on 
6-week follow-up (1) concerned 18,895 patients (97.4% of the 
rar:?omized population) for whom complete clinical data were 
avariable at that time. Because a substantial proportion of 
patients reported as lost to follow-up were subsequently traced 
(423 of 499), the present report includes information on the 
6-month survival of 17,940 (99.7%) patients, of the 18,006 still 
alive at 6 weeks: 15,679 patients were evaluated clinically by 
the responsible cardiologists, but for 2,261 patients only sur- 
vival data obtained through the census offices were available. 
Lisiwpril versus no lisinopril. The results in terms of the 
combined end point of mortality and severe ventricular dys- 
function, which was the main outcome measure of the study at 
6 months, are reported in Table 1 together with the corre- 
sponding h-week figures. Among patients randomized to re- 
ceive lisinopril, 18.1% died or developed severe ventricular 
dy&mction within 6 months (1,743 of 9,646) versus 19.3% 
among those not treated with lisinopril (1,866 of 9,672). The 
difference (6.2% reduction in the combined end point) was 
statistically significant (2p = 0.03). Among lisinopril-allocated 
patients there were 123 fewer events than in the no-lisinopril 
group; such a reduction was distributed equally among the 
different components of the combined end point: -46 deaths, 
-37 patients with clinical heart failure, -40 patients with 
severe left ventricular dysfunction (defined as an ejection 
fraction ~35% or as a dyskinesia score ~45% in the small 
group of patients in whom ejection fraction was not measured). 
Although the difference in terms of mortality was lower at 
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Table 1. Six-Week and Six-Month Combined End Point Rates in Lisinopril and No-Lisinopril Groups 
6 Weeks 6 Months 
Liiinopril No Lisinopril OR p Value Lisinopril No Lisinopril 
(II = 9.646) 
p Value 
(n = 9,672) (95% Cl) (two-tailed) (a = 9,646) (II = Y,672) (tuo-tailed) 
Total events 1,495 (15‘5) 1,629 (16.8) 0.89 0.04 1,743 (18.1) 1,866 (19.3) 0.92 0.03 
(0.79-0.99) (0.86-099) 
Deaths 619 (6.4) 693 (7.2) 882 (9.1) 928 (9.6) 
CHF 366 (3.8) 351’ (3.7) 521 (5.4) 55x (5.8) 
EF 535% 451 (4.7) 530 (5.5) 320 (3.3) 358 (3.7) 
AD score 245% 59 (0.6) 52 (0.5) 20 (0.2) 22 (0.2) 
Data presented are number(B) of patients or odds ratio (OR) with 95% confidence interval (CO. AD = akinesiaidyskinesia: CHF = congestive hean failure: EF = 
ejection fraction. 
6 months with respect to the corresponding 6-week figures (8 Transdermal glyceryl trioitrate versus no glyceryl trini- 
lives saved per i,OOO treated patients at 6 weeks vs. 5 per 1,000 hate. Table 4 presents the 6-month combined end-point re- 
at 6 months), the incidence rate of patients with clinical heart sults for the glyceryl trinitrate versus no-glyceryl trinitrate 
failure was slightly lower at 6 months among lisinopril- groups. At 6 months no significant difference in benefit was 
allocated patients than among control subjects (5.4% vs. 5.8% seen in the combined end point between the group of patients 
respectively), while no difference was present at 6 weeks (3.8% alloca:cd to receive 6 weeks of hansdermal glyceryl trinitratc 
vs. 3.7%). treatment and control subjects (18.4% vs. 18.9%, 2p = 0.39). 
The benefit of lisinopril treatment at 6 weeks was confirmed 
for the elderly and in women after 6 months (Table 2). There 
was a significant reduction of the combined end-point rate 
among patients over 70 allocated to lisinopril with respect to 
those allocated to no lisinopril(30.6% vs. 33.8%, 9.5% reduc- 
tion, 2p = 0.01). The pattern for women was similar; the 
combined end-point rate was 25.4% among women allocated 
to liiinopril versus 28.0% among women allocated to no 
lisinopril (9.3% reduction, 2p = 0.05). 
With respect to the high risk populations, although the 
6.2% reduction in the combined end point observed in women 
was not statistically significant (2p = 0.22), a significant 
reduction in terms of combined end point was confirmed 
among elderly patients allocated to glyceryl trinitrate with 
respect to no-glyceryl trinitrate group (30.9% vs. 33.58,7.8% 
reduction, 2p = 0.04) (Table 5). 
There were no significant differences between patients 
allocated to lisinopril or no lisinopril in rates of reinfarction, 
postinfarction angina, sustained ventricular tachycardia and 
revascularization procedures (percutaneous transluminal an- 
gioplasty, coronary artery bypass surgery) (Table 3). 
The h-month rates of sustained ventricular tachycardia, 
reinfarction, postinfarction angina and revascularization pro- 
cedures did not differ significantly between glyceryl trinitrate 
and no-glyceryl trinitrate group-allocated patients (Table 3). 
Lisinopril plus tmnsdemal $ mryl trioitmte versus nei- 
ther. The combined end point rates for control subjects, 
glyceryl trinitrate alone, lisinopril’alone and the combination 
Table 2. Six-Month Combined End Point Rates by Age and Gender in Lisinopril and No-Lisinopril Groups 
OR p Value 
liSiIl0pIil No Lisinopnl (Y5f-i Cl) I-otd (G) (two-t&d) 
Patienti >70 yr 
Total events 
Deaths 
CHF 
EF r35?& 
AD score 2455; 
Women 
Total evwfP 
Deaths 
CHF 
EF r35?70 
AD score 2454 
79012,585 (30.6) 896f2.649 (33.E) 0.86 1.68615.234 0.01 
(0.77-0.97) (32.2) 
5 18 (20.0) 545 (20.6) 
1% (7.6) 258 (9.7) 
70 (2.7) x8 (3.3) 
6 (0.2) 5 (0.2) 
54412.144 (25.4) 59812.132 (28.0) 0.87 1.142~4,276 0.05 
(0.76-1.00) (26.7) 
323 (15.1) 360 (16.9) 
165 (7.7) 184 (8.6) 
51 (2.4) 49 (2.3) 
5 (0.2) 5 (02) 
Data presented are number @) of pat&t& unless o&mire iadieated. Abbreviatiorts as in Table 1. 
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Tabte 3. Six-Month Clinical Events 
(n “E63) 
Reinfarcdon 445 (4.6) 
Postinfarction angina 2,612 (27.0) 
Sustained VT 219 (2.3) 
Angioplasty 
Bypass sargely 
379 (3.9) 
437 (4.5) 
No GTN 
(n = 9.655) 
451 (4.7) - 
2.726 (28.2) 
251 (2.6) 
374 (3.‘)) 
446 (4.6) 
0.99 
(&S6-1.13) 
O.Y4 
(ML-1.00) 
0.87 
(0.72-1.04) 
1.01 
(0.X8-1.17) 
0.98 
(ILXS-1.12) 
- 
Lisinopril No tisinopril OR 
(n = 9,646) (n = 9,672) (95? Cl) 
4.54 (4.7) 442 (4.6) I.03 
(0.90-LIH) 
2,711 I (28.0) 2.637 (27.3) I.04 
(0.97-1.11) 
124 (2.3) 246 (2.5) (I.‘)1 
(0.76-1.09) 
383 (4.0) 370 (3.X) I .04 
(0.90~I.2lJ) . 
4h3 (4.8) 420 (4.3) 1.11 
(O.Y7-1.27) 
Data presented are number (%) of patientc. unlc~~ othcvise indicated. FTN = glycql trinirratc: VT = ventricular tachycardia; other ahhrwiations as in Table I. 
of lisinopril plus g’)‘ce?jl trinitrate are shown in Table 6. The 
combination of lisitopril and transdermal glyceryl trinitrate 
produced an 8.7% reduction in the combined end point events 
rate compared with the control group (17.8% vs. 19.5%. 2p = 
0.03). 
classes (mainly calcium antagonists and beta-adrenegic block- 
ing agents) whose indications are partially overlapping with 
those of angiotensin-converting enzyme inhibitors. 
The combination of lisinopril and transdermal &eryl 
trinitrate was associated with an even greater effect on the 
combined end point both in elderly patients (29.2% vs. 35.2%. 
i7% reduction, 2p = 0.001) and in women (24.9% vs. 29.3%, 
15% reduction, 2p = 0.02) (Table 7). 
Six-month prescriptions of cardiovascular drugs. The 
overall picture of the prescription patterns at 6 months is 
presented in Table 8, which includes data on trial treatments as 
well as on the other cardiovascular drugs. The information 
available for the 15,679 patients who underwent a clinical visit 
at 6 months is presented according to the four-way scheme to 
allow a more thorough evaluation of the possible confounding 
by unbalanced distributions. A higher proportion of patients 
randomized to either lisinopril or nitrates appear to have been 
exposed to the originally allocated drug. The main indications 
for angiotensin-converting enzyme inhibitors at 6 months were 
hypertension (48.6%) and clinical heart failure/left ventricular 
dysfunction (34%), whereas the main indications for nitrates at 
6 months were angina (48.1%) and left ventricular dysfunction 
(15.4%). As expected, a slightly lower proportion of lisinopril- 
allocated patients appear to have been exposed to therapeutic 
Of the patients with angiotensin-converting enzyme mhib- 
itors pres:ribed at 6 months, 47.7% of the patients allocated to 
lisinopril were receiving angiotensin-converting enzyme inhib- 
itors since the 6-week visit versus and 30.3% of those allocated 
to no iisinoprii. A similar trend was found for glyceryl trini- 
trate, uhere 49.8% of the patients allocated to this drug who 
were treated with nitrates at 6 months had actually been 
consuming nitrates since the 6-week visit versus 41.OY0 of 
no-glyceryl trinitrate-allocated patients. 
Six-month outcome of patients with or without left vent&- 
alar failure/dysfunction at 6 weeks. Table 9 shows the total 
mortality rate and the rate of patients with severe heart failure 
(functional classes III and IV) between 6 weeks and 6 months 
stratified by the presence at 6 weeks of signs or symptoms of 
left ventricular failure or dysfunction, or both. Total mortality 
and severe heart failure rates among patients with asymptom- 
atic depressed left ventricular ejection fraction (~35%) or 
marked regional wall motion abnormalities (~45%) was over 
twice that among patients classified at 6 weeks as patients with 
no complications. The presence of symptoms of heart failure at 
6 weeks appears to be even more predictive of an unfavorable 
prognosis. 
Tabte 4. Six-Week and Six-Month Combined End Point Rates in Glyceryl Trinitratc and Ko-Glvr~nrl T&&K& G~I,~Q .._ -..- ._ -.,-- . , .  _ . . . . . I .  I . _  y . v ” r ”  -- 
6 Wreks 6 Months -~ -- 
(n ::63) 
No GTN OR p Value No GTN OR 
(n = 9,655) (95% Cl) (two-tailed) (” z63) 
p Value 
(n = 9.655) (YSS; CI) (iwwailcd) 
Total events 1,524(15.8) 1,600 (16.6) 0.94 0.13 1.782(18.4) 1,827 (1X.9) 0.97 n.39 
(0.X7-LU2) 
Deaths 
(0.90~I.04) 
639 (6.6) 673 (7.0) 
CHF 
x95 (9.3) 915 (‘).!I) 
357 (3.7) 3413 (3.8) 
EF ~3.5% 
548 (5.7) 531 (5.5) 
483 (5.U) 498 (5.2) 
AD score 245% 
318 (3.3) 36u (3.7) 
45 (0.5) 66 (0.7) 21 (0.2) 21 (0.2) 
Data presented are number (%) of patient& unless othetwie indicated. .Abbrcviations a in Tables I and 3. 
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Table 5. Six-Month Combined End Point Rates by Age and Gender in Glyceryl Trinitrate and 
No-Cilyceryl Trinitrate Groups 
p Value 
GTN No GTN (95%) TOM (two-tailed) 
Patients >70 yr 
Total events 802&.599 (30.9) 884/2635 (33.5) 0.88 1,686/5234 0.04 
(0.79-0.99) (32.2) 
Deaths 50; (19.6) 554 (21.0) 
CHF 214 (X.2) Ml (9.1) 
EF ~35% 13 (2.8) 85 (3.2) 
AD smre z 45% 6 (0.2) 5 (0.2) 
W0Rlen 
Total events 55812,156 (25.9) 584/2.120 (27.6) 0.92 1,142;4276 0.22 
(0.x4Li.05) (26.7) 
Deaths 327 (15.2) 356 (16.8) 
CHF 178 (8.3) 171(8.1) 
EF ~35% 48 (2.2) 52 (2.5) 
AD score 2 45% 5 (0.2) 5 (0.2) 
Data presented are number (B) of patients, unless otherwise indicated. Abbreviations as in Tablei 1 and 3. 
Discussion 
Effects of randomiaed treatments. The GIN-3 results at 6 
months are substantially consistent with those on mortality at 
6 weeks. The early treatment of unselected acute myocardial 
infarction patients with lisinopril leads to a small but statisti- 
cally significant benefit in terms of the combined end point of 
mortality plus severe ventricular dysfunction. Both compo- 
nents of the combined end point contribute to the overall 
result, which also applies (symmetrically with the observations 
at 6 weeks) to the predefined higher-risk populations (women 
and elderly subjects). 
With respect to the other main hypothesis tested in the 
study, no independent beneficial effects are found for glyceryl 
trinitrate, although the safety of the combination of glyceryl 
trinitrate and lisinopril is conhrmed. 
Overall, the results obtained on the combined end point 
confirm those on mortality of the ISIS-4 trial (8) in which a 
two-stage assessment was not planned, although the double- 
blind design implied the discontinuation of the randomized 
treatments: the findings on survival at the end of the treatment 
period (at 35 days) are reported unchanged up to 1 year (8). A 
comparison of these data with those of the Survival of Myo- 
cardial Infarction Long-Term Valuation (SMILE) trial (I l), 
which showed an increasing knefit among patients allocated 
to zofenopril over 11 months after drug discontinuation, would 
be difficult because of the rather diiferent characteristics of 
that population (selected anterior acute myocardial infarction 
patients not exposed to thrombolysis). 
The analysis of the different componems of the combined 
end point suggests some interesting observations, mainly with 
respect to the effects of an early treatment with angiotensin- 
converting enzyme inhibitors on mortality and on ventricular 
function. The ditIerence in terms of mortality was less marked 
at 6 months than at 6 weeh; in contrast, although after 6 weeks 
there was no evidence of an effect on the percent of patients 
with clinical heart failure. a reduction was shown at 6 months 
among patients taking lisinopril. The improvement in left 
ventricular function seen at 6 weeks-he smaller fraction of 
subjects with a depressed ejection fraction (4.7% vs. SS%)-in 
the group randomized to lisinopril has probably determined 
the lower rate of patients subsequently developing an overt 
heart failure. 
If the mechanisms of the early reduction of mortality are 
still not clear (12,13), the better profile in terms of ventricular 
Table 6. Six-Month Combined End Point Rates for Four-Way Comparkm 
Control GTN Lisinoptil 
in = 4,828) in = 4,844) (!I = 4,827) 
Lisinopril * GTN 
(n = 4,819) 
Total events 940 (19.5) 926 (19.1) 88-i (18.4) Wi(17.8) 
OR (95% Cl) I 0.98 0.93 039 
(0.xX-1.08) (0.84-1.03) (0.81-0.99) 
p value (t-w-tailed) 0.03 
Deaths 461(9.7) 461(9.5) JQB (93) 434 (9.0) 
CHF 275 (5.7) 283 (5.8) 2% (53) 265 (5.5) 
EF ~~35% It% (3.9) 172 (3.6) 174 (3.6) 146 (3.0) 
AD sore 245% 12 (0.2) lO(O.2) 9 (02) 11(02) 
I?ata presented are number (W) of patients, unless othetwise indicated. Abbkations as in Tables I and 3. 
342 GISSI-3 GROUP JACC Voi. 27, No. 2 
LISINOPRIL IN GISSIJ February 1’)96:337-44 
Table 7. Six-Month Combined End Point Rates hy Age and Gender 
Control GTN Liainopril Lisinopril + GTN 
Patient5 170 yr old 
Total events 
OR (9% Cl) 
p value (two-tailed) 
Deaths 
CHF 
EF ~3.5% 
AD .wore %Wi 
Women 
Total events 
OR (Y5? Cl1 
p value (hw-tailed) 
Deaths 
CHF 
El- ~35~; 
AD scoce ~45? 
46S’l.32? (35.2) 
I 
278 (Y.(1) 
I37 (10.4) 
4Y (3.7) 
I (0.1) 
3u6~l.u-l6 (29.3) 
187 (17.9) 
8’) (8.5) 
27 (2.6) 
3 (0.3) 
431’1.327(?2.5l 
0.89 
(0.75-l 04) 
267 (30.1) 
121 (0.1) 
39 (2.9) 
4 (0.3) 
276(X0) 
Ill3 (7.X) 
36 (2.7) 
4 (II3 
?Y::l.fM (26.9) 278M74 (25.9) 
0.89 0.84 
(O.iJ-1.07) (O.70-1.02; 
173(15.91 
9s (X.7) 
22 (3.0) 
2 (0.2) 
169~15.7) 
S2 (7.6) 
2.5 (2.3) 
2 IO.21 
4lY’l.313(3l.Y) 
II.86 
(0.7.~1.02) 
371’1,272 (29.2) 
0.76 
(U.hJ-IEm) 
0.001 
242 (1Y.O) 
W(7.3) 
34 (2.7) 
2 (I).?) 
?66:I.070 (24.9) 
O.&l 
(U.hh-0.97) 
11.02 
154 (14.4) 
83 (7.X) 
26 (2.4) 
3 w.31 
Data presented are number (G) of patients, unless otherwise indicated. Abhrcviarions as in Tables I and 3. 
function at 6 months could be explained by the expected 
favorable influence of angiotensin-converting enzyme inhibitor 
trealment on left ventricular remodeling processes. In this 
sense, the analysis of the echocardiographic exammations 
included in the GISSI-3 protocol suggests that patients ran- 
domized to lisinopril may be protected against the left ventric- 
ular dilation that follows acute myocardial infarction. Smaller 
left ventricular volumes were observed at the 6-month 
follow-up visit among patients allocated to lisinopril compared 
to control subjects even following drug withdrawal (14). 
Both the findings and the hypotheses must certainly be read 
now in the overall context of the results of the Survival and 
Ventricular Enlargement (SAVE) (15), Acute Infarction 
Ramipril Efficiency (AIRE) (16), and Trandolapril Car- 
diac Evaluation (TRACE) (17) trials, which recommend 
angiotensin- converting enzyme inhibitor treatment in patients 
with clinical signs of congestive heart failure or even in those 
with asymptomatic left ventricular dysfunction. In GISSI3, 
many patients with left ventricular dysfunction assigned to 
lisinopril treatment were maintained on the drug, and several 
control patients started angiotensin-converting enzyme inhib- 
itor agents after 6 weeks. 
Different patterns of medication use. The issue of the 
possible Impact on outcome of the treatments prescribed 
behveen 6 weeks and 6 months should be evaluated by 
considering ‘iable 8. Nonstrict adherence to the withdrawal 
recommendations was to some extent expected, mainly in the 
lisinopril-treated group: An angiotensin-converting enzyme 
inhibitor treatment began to be recommended for heart fail- 
ure/ventricular dysfunction during the trial period (late 1992), 
and the protocol had already explicitly stressed the priority of 
guaranteeing that patients receive the best treatments (as soon 
as the related evidence was available) rather than strict com- 
pliance with the withdrawal rule planned by the GISSIJ 
protocol. A letter concerning this point was also sent to the 
investigators to alert them in as timely a way as possible to the 
results and the implications of the SAVE trial (14). On the 
other hand, it is reasonable that continuation of angiotensin- 
converting enzyme inhibitor treatment could be considered a 
useful option for hypertensive patients. Analysis at 6 months of 
Table 8. Patients Taking Cardiovascular Drugs at 6-Month Follow-Up by Trial Treatment* 
Control GTN Lisinopril Lisinopril + GTN 
Dw (It = 3,902) (n = 3,920) (n = 3,923) (n = 3,934) 
ACE inhibitors 662 (li.0) 614 (15.7) 1.334 (34.0) l,4lO(3S.8) 
Nitrates 1,251 (32.1) I.652 (42.1) 1,093 (27.9) 1.672 (42.5) 
Digoxin 249 (6.4) 272 (6.9) 2SO (6.4) 249 (6.3) 
Diuretics 540(13.X) S31(13.5) 514(13.1) 470(11.9) 
Ca antagonists I.073 (27.5) I.076 (27.41 930 (23.7) Yll(z3.2) 
Beta-blockers I.185 (30.4) I,1 12 (28.4) I,01 t (25.X) 9s7 (24.3) 
Aspirin 2,042 (52.3) 2,Oi9(SlS) 2.046 (52.2) 1,972 (50. I ) 
‘For 15,679 patients; patienb taking different claws of drugs are counted more than owe. Data presented are 
number (%I) of patients. ACE = angiotensinconverting enzyme: Ca = ealcb.mt: GIN = glyceryl tfinitrate. 
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T&e 9. Six-Month Mortality and Heart Failure Rates in Patients 
With/Without Signs or Symptoms of Left Ventricular Dyshmaion Appendix 
Status at 6 mo 
Status at 6 wk (n = 2,756)’ Deaths CHF 
Symptomatic heaa failure (n = 720) 94 (13.1) I19 ( 16.5) 
Asymptomalic left ventricular dysfunction 46 (4.2) 92 (8.4) 
(II = 1.092) 
No complications (n = 13,429) 1%(1.5) ,%I (2.2) 
l Aqmptomatic patienls without echocardiography. Data presented are 
number ($6) of patients. CHF = congestive heart failure: LVD = left ventricular 
dysfunction. 
Study Organization 
Steering Committee. C. De Vita, P. F. Fazzini, E. Geraci, 
L. Tavazzi, G. Tognoni and C. Vecchio (Chairman). Safety and Bata 
Mo~itoriog Committee. R Boeri. G. D’Amim, U. Loii E. Marubini, 
L. Pagliaro and F. Rovelli (Chainnan). !kkntifje and organizing 
SeeWariat. M. C. Fran&, R. Latini, A P. Ma&on;, F. Mauri and 
A. Volpi. Data Management PPE Anal+. S. Bulera. E. Negri, 
E. Nicolis, E. Santoro and L. Santoro. T.zkml %ta WG Coding lnrl 
Echocardiograpbic Data Revision. A. Asc.me, E. Bonfanti, T. 
Capella, A. Casati, A. Corato, E. Gardinale, M. Negriaii A. Nob&i L. 
Staszewsly, M. Tavanelli, D. Torta and G. Zuanetti. D 
Quality Control Gruup. G. Gambelli, L Moron;. J. J. Pellanda and 
F. Pietropaolo. Regbnai Clii Monitors. E. Balli, A, Barbieri, 
S. Bechi, M. Carrone. M. Catanzaro, L Fasciolo, C. Fresco, A Ghiani, 
G. lacuitti, A LeddP, G. Levantcsi, L Moroni, P. Pa&i, P. Peci, 
F. Pizetti, A. Sagone. F. Turazza, A Wella and M. Villella S&n& 
Committee &W Side bjects. N. B&o, M. Disertori, S. Frezzati. 
S. Garattini. P. Marino, A Maw-i, G. Mazzotta, G. Ntiosi. S. Pi&Ii, 
G. P. Sanna and F. Va!qussa. International Ad~+sory Boa& H. J. 
Dargie, R. Peto. S. Pocock, P. Sleight and S. Yusuf. 
the section of the data collection forms concerning treatment 
indications confirms this hypotheses. Overall, however, the 
prescription burden of cardiovascular drugs appears similar in 
the two populations. 
Outcome profile of patients with or witbout signs and 
symptoms of left ventricular dysfunction. The 6-month 
follow-up period planned by the GISSI-3 study made it possi- 
ble to confirm the prognostic relevance of left ventri.:uiar 
dysfunction detected echocardiographicaily after myocardial 
infarction. Total mortality and severe heart failure (functional 
classes III or IV) rates appeared to he higher among the 
patients with asymptomatic depressed left ventricular ejection 
fraction or marked regional wall motion abnormalities at 6 
weeks. However, the presence of clinical symptoms of heart 
failure appeared to be the strongest predictor of a poor 
prognosis. 
Conclusions. Although the systematic administration of 
glyceryl trinitrate started early and continued for 6 weeks after 
an acute myocardial infarction does not provide an appreciable 
clinical advantage, early treatment with lisinopril of an un- 
selected population of patients with acute myocardial infarc- 
tion with no treatment contraindications appears to improve 
their prognosis with respect to mortality and severe left 
ventricular dysfunction, and this effect seems to carry over the 
first 6 months from randomization, even after treatment 
withdrawal. The mortality reduction is mostly obtained in the 
first few days of lisinopril treatment (12,13), but the improve- 
ment in terms of ventricular function (clinical and/or instru- 
mental) becomes more evident at a later stage (i.e., at the 
6-month follow-up visit). 
Further, with respect to the other prespecified analyses, the 
combination of glyceryl trinitrate and lisinopril is confirmed to 
be safe and suggestive of some additive, beneficial effect. 
Similarly, the data presented here seem to confirm the favor- 
able profile ‘of mortality and severe left ventricular dysfunction 
obtained in elderly patients and in women with lisinopril 
treatment. 
These observations fit the recommendations on the use of 
angiotensin-converting enzyme inhibitors in the acute and 
postacute phase of acute myocardial infarction, formulated in 
an international meeting of the investigators activeiy involved 
in the main published angiotensin-converting enzyme inhibitor 
ttirds (13). 
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